Mirati Therapeutics, Inc. (MRTX)

175,68 -0,63 (-0,35%) Al 10:56AM EDT. Mercato aperto.

Mirati Therapeutics, Inc.

3545 Cray Court
San Diego, CA 92121
United States
858 332 3410
http://www.mirati.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 199

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Charles M. Baum M.D., Ph.D.	Founder, Pres, Head of R&D & Director	1,13M	13,06M	1958
Mr. Daniel R. Faga	Chief Operating Officer	1,16M	N/D	1980
Dr. James G. Christensen Ph.D.	Chief Scientific Officer	820,05k	2,78M	1968
Mr. Benjamin J. Hickey	Chief Commercial Officer	798,32k	N/D	1976
Mr. David D. Meek	CEO & Director	N/D	N/D	1963
Ms. Vickie S. Reed	Sr. VP & Chief Accounting Officer	N/D	N/D	1962
Temre Johnson	Director of Investor Relations & Corp. Communications	N/D	N/D	N/D
Ms. Reena R. Desai	Gen. Counsel & Corp. Sec.	N/D	N/D	N/D
Ms. Kristin Gustafson	Chief HR Officer	N/D	N/D	N/D
Dr. Kelly Covello Ph.D.	VP & Head of Medical Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Mirati Therapeutics, Inc. al 26 settembre 2021 è 8. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 9; diritti degli azionisti: 4; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.